The chairman and general manager of Sichuan Fuzheng Pharmaceutical Co., Ltd., a well-known pharmaceutical company, resigned.

On August 20th, Sichuan Fuzheng Pharmaceutical Co., Ltd. announced the resignation of its chairman and general manager, saying that on August 10th the company's board of directors received a resignation report from Sun Jilin, chairman of the board of directors, effective August 10, 2020.
same day, Sun Jilin resigned as general manager of Sichuan Fuzheng Pharmaceuticals, effective August 10.
resignation, he will no longer hold other positions in the pharmaceutical industry.
, Sun Jilin holds 1,799,117 shares, or 7.71 percent of the shares, according to the announcement.
company's 2019 annual report, according to the company's 2019 annual report, after the real control of Sun Jilin held a stake in the company, at one point reached 74.23 percent, with absolute control.
As the company's controller, Sun Jilin can directly or indirectly influence the company's major decisions through the exercise of voting rights, such as major foreign investment, related transactions, appointment and removal of persons, financial management, corporate strategy, etc.
public information shows that Sun Jilin, born in October 1963, Han nationality, graduated from Chongqing Pharmaceutical School in Sichuan Province in 1981, graduated from Chengdu University of Traditional Chinese Medicine in 1992 with a bachelor's degree in pharmacy, and obtained a master's degree in business administration from the University of Electronic Science and Technology in 2010.
From 1993 to 1998, he served as Deputy General Manager and Sales Manager of Chengdu Dikang Pharmaceutical Co., Ltd., from 1998 to 2006, as Chairman and General Manager of Sichuan Dikang Technology Pharmaceutical Co., Ltd., from 2007 to March 2015, as General Manager of Sichuan Fuzheng Pharmaceutical Co., Ltd., and from March 2015, he was chairman and general manager of Sichuan Fuzheng Pharmaceutical Co., Ltd.
on the same day, Sichuan Fuzheng Pharmaceuticals also announced the appointment of a new chairman and general manager - The 17th meeting of the second board of directors of Fuzheng Pharmaceuticals elected Sun Zheng as the chairman and general manager of the company, the term of office is consistent with the term of office of the company's second board of directors, effective August 15, 2020.
holding 10,794,699 shares, or 46.27% of the share capital, and is a controlling shareholder, assisting the General Manager in the sales department since 2016.
announced that the election of Sun Zheng as chairman and appointment as general manager is in line with the actual development needs of the company, help to promote the company's management and improve corporate governance.
, born in September 1988, han, graduated from the University of Manchester in 2011.
from 2011 to 2013, he worked for United News Securities Company, from 2013 to January 2016, as the general manager of Sichuan Fuzheng Pharmaceutical Co., Ltd., and from January 2016 to August 2020, he was assistant manager of the marketing management department of Sichuan Fuzheng Pharmaceutical Co., Ltd., assisting the general manager in charge of sales.
According to public information, Sichuan Fuzheng Pharmaceuticals, founded in 2007, legal person Sun Jilin, September 24, 2007, the predecessor of JaneYang County Jianqu factory was transformed into Sichuan Fuzheng Pharmaceutical Co., Ltd.
11, 2015, the company changed its name to Sichuan Fuzheng Pharmaceutical Co., Ltd.
The annual report of local Chinese medicine drinking tablet enterprises shows that the main business of Sichuan Fuzheng Pharmaceutical Industry is the production and sale of Chinese medicine tablets, quarials, toxic Chinese medicine tablets - the main projects include, Taodial Chinese medicine seed seedling breeding, standardized planting, wild breeding, wild domestication, crafting technology, quality standards research and development, clinical verification and promotion.
The main products are: fermented Traditional Chinese medicine (Jianqu, Six Gods, Bile Nanxing, Fried Jianqu, Coking Six Gods, etc.), single-party drink tablets (Snow Bile, Unique Taste, Golden Buckwheat, Yellow Grass, Buckwheat Pollen, Red Sky, etc.), Children's Chinese medicine tablets (Snow Bile, Six Gods, Coking Six Gods, Fried Six Gods, etc.).
According to its 2019 financial results, as of December 31, 2019, Sichuan Fuzheng Pharmaceutical's total assets amounted to 77.9528 million yuan, an increase of 27.62 percent over the end of the previous year, mainly due to the acquisition of 100% of the shares of Sichuan Yuhong Pharmaceutical Development Co., Ltd., a subsidiary of Fuzheng Chinese Medicine fixed assets and intangible assets increased by 18.0872 million yuan.
2019, Sichuan Fuzheng Pharmaceuticals achieved revenue of 110.2663 million yuan, of which the top five customers accounted for 20.21% of their total main business income.
2018, Sichuan Fuzheng Pharmaceuticals' operating income was 88.5656 million yuan, an increase of 65.89 percent over the same period last year, mainly due to the increase in operating income of fermented Chinese medicine tablets in small packaging and unilateral beverage tablets due to increased efforts to promote specialized clinical scholarship.
net profit was RMB9.1231 million, an increase of RMB2.9165 million over the same period last year.
, according to Cypress Blue review of its previous years' earnings, overall, Sichuan Fuzheng Pharmaceuticals' revenue is in a year-on-year upward trend.
However, in its annual report, the pharmaceutical industry also mentioned the risks it faced, mainly market competition risks, raw material supply concentration and price fluctuations, resource shortage risks, policy changes caused by the risk.
said that the short-term sharp fluctuations in the price of raw materials for Chinese herbal medicines will lead to reduced supply and higher prices, which in turn will affect the cost and operation of the company's products.
, however, compared with other areas of the pharmaceutical industry, the state's support for the Chinese medicine industry is significantly greater.
Alever, at the same time, in order to promote the long-term sustainable development of the Chinese medicine industry, the state has also introduced corresponding industry norms and measures, such as the requirements of Chinese herbal raw materials to implement traceability management, the implementation of comprehensive testing of Chinese herbal raw materials and improve testing standards, medical institutions on the procurement policy of Chinese medicine tablets, there may be future national policy adjustment on the business environment adversely affect the risk.
Indeed for most Chinese medicine tablet enterprises, with the implementation of the new version of the drug management law, the new version of pharmacopeia, the standardization of the Chinese medicine drinking tablet industry is a long-term situation, in the process of standardization, some small drinking tablet enterprises are also facing the pressure of being eliminated and integrated.
.